This leads to the hypothesis that disturbances in the integrity of the blood–brain barrier could lead to an access of these autoantibodies to the particularly GFAP-rich areas, so that these autoantibodies could then acquire a pathological function in the development of PD. This evidence concerns the gene GFAP and Parkinson disease.